Cipher receives Patent Notice of Allowance for CIP-ISOTRETINOIN
09-Jun-2008
The patent includes claims related to the reduced food effect of CIP-ISOTRETIOIN relative to currently marketed formulations.
"Having the U.S. patent allowed represents an important milestone on our path to commercialization for CIP-ISOTRETINOIN," said Larry Andrews, President & CEO of Cipher. "It also reinforces that the product is truly differentiated from currently marketed formulations."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.